Head to Head Analysis: National Research (NASDAQ:NRC) & HedgePath Pharmaceuticals (NASDAQ:HPPI)

HedgePath Pharmaceuticals (OTCMKTS:HPPI) and National Research (NASDAQ:NRC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Dividends

National Research pays an annual dividend of $0.76 per share and has a dividend yield of 1.2%. HedgePath Pharmaceuticals does not pay a dividend. National Research pays out 73.1% of its earnings in the form of a dividend.



Earnings and Valuation

This table compares HedgePath Pharmaceuticals and National Research’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
HedgePath Pharmaceuticals N/A N/A -$4.55 million N/A N/A
National Research $119.69 million 12.68 $30.05 million $1.04 58.69

National Research has higher revenue and earnings than HedgePath Pharmaceuticals.

Analyst Recommendations

This is a breakdown of current ratings and price targets for HedgePath Pharmaceuticals and National Research, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HedgePath Pharmaceuticals 0 0 0 0 N/A
National Research 0 1 0 0 2.00

Profitability

This table compares HedgePath Pharmaceuticals and National Research’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
HedgePath Pharmaceuticals N/A N/A -246.03%
National Research 24.59% 124.11% 28.56%

Institutional and Insider Ownership

36.0% of National Research shares are held by institutional investors. 4.8% of HedgePath Pharmaceuticals shares are held by company insiders. Comparatively, 4.5% of National Research shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

HedgePath Pharmaceuticals has a beta of -1.16, suggesting that its share price is 216% less volatile than the S&P 500. Comparatively, National Research has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500.

Summary

National Research beats HedgePath Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

HedgePath Pharmaceuticals Company Profile

HedgePath Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers and non-cancerous proliferation disorders in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It also develops super bioavailability (SUBA)-itraconazole oral capsules for patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida. HedgePath Pharmaceuticals, Inc. is a subsidiary of Mayne Pharma Ventures Pty Ltd.

National Research Company Profile

National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Company’s portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The Company’s clients range from acute care hospitals and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The Company derives its revenue from its annually renewable services, which include performance measurement and improvement services, healthcare analytics and governance education services.

Receive News & Ratings for HedgePath Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HedgePath Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.